TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04157933
Drug: 009-A0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled placebo via Staccato aerosol, Dose 0 (placebo) each day for first 5 days, then 3 doses Dose 0 (placebo) q 2 hr on Day 6
Study: NCT05846698
Drug: Luo-Bu-Fu-Ke-Bi-RI Pill
Normalized name: Osteo Bi-Flex Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 pills twice daily
Study: NCT02132533
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally, then placebo orally after 90 minutes if still contracting. Continue placebo orally every 4 hours after the first dose for 48 hours.
Study: NCT01026129
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bolus dose of intravenous remifentanil 0,25 mcg/kg given once before emergence of general anesthesia.
Study: NCT01026129
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bolus dose of intravenous remifentanil 0.5 mck/kg given once before emergence of general anesthesia.
Study: NCT02397447
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: 2000 mg per day for three months
Study: NCT03568721
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: prescription of ibuprofen 400 mg
Study: NCT03568721
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: prescription of acetaminophen 500 mg
Study: NCT00759122
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching capsules containing placebo 37.5 mg. WERE prepared by the UCLA Pharmacy for the initial phase of the study. After a one-week placebo lead-in, subjects WERE randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects received four capsules daily (subjects achieved a dose of 150 mg. of venlafaxine after 10 days). The first dose was administered in the morning, with subsequent capsules added on a b.i.d. schedule.
Study: NCT00957788
Drug: NST-001
Normalized name: GLOVE NITRILE SM PFREE NSTERL TX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of different dosages of drug.
Study: NCT00004221
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00269906
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01606423
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally, single dose
Study: NCT01606423
Drug: LY2409021
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally, single dose
Study: NCT04435964
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients treated as per clinical prescription with immunocheckpoint inhibitors (ICI) irrespective of treatment schedule, either as single agent or in combination with chemotherapy and/or radiotherapy
Study: NCT05614440
Drug: Only local anesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using articain HCL for inferior alveolar nerve block
Study: NCT02459080
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04511624
Drug: IBI112 dose1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: IBI112 SC dose1 Drug:placebo
Study: NCT04511624
Drug: IBI112 dose2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: IBI112 SC dose2 Drug:placebo
Study: NCT04511624
Drug: IBI112 dose3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: IBI112 SC dose3 Drug:placebo
Study: NCT04511624
Drug: IBI112 dose4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: IBI112 SC dose4 Drug:placebo
Study: NCT04511624
Drug: IBI112 dose5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: IBI112 IV dose5 Drug:placebo
Study: NCT04511624
Drug: IBI112 dose6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: IBI112 SC dose6 Drug:placebo
Study: NCT04511624
Drug: IBI112 dose7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: IBI112 IV dose7 Drug:placebo
Study: NCT01439867
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care may have included vitamin D sterols (25 OH vitamin D and/or 1-25 OH vitamin D and its analogs) at the discretion of the investigator.
Study: NCT01065467
Drug: LBH589
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken orally three times per week.
Study: NCT01613690
Drug: NVA237
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVA237 is administered via a BREEZHALER device
Study: NCT04112706
Drug: CPP-ACP
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CPP-ACP WAS APPLIED AFTER TOOTH BLEACHING
Study: NCT02763215
Drug: Standard of Care Medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care medications could include penicillamine, trientine, zinc, or a combination of a copper chelator and zinc.
Study: NCT01780454
Drug: MEDI-507
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-Cell Depleting Agent
Study: NCT03121820
Drug: Memantinol tablets, 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioequivalence Memantine Hydrochloride (JSC GEROPHARM, Russia) 20 mg film-coated tablets fasting condition
Study: NCT00672685
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMEGA-3 placebo
Study: NCT04380818
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/24h for 3 days
Study: NCT04380818
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (methylprednisolone/dexamethasone/prednisone)
Study: NCT04380818
Drug: Low molecular weight heparin
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: low molecular weight heparin (LMWH) in prophylaxis of venous thromboembolism
Study: NCT01467310
Drug: GSK1120212
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 to 2.0 mg taken orally every day for seven days.
Study: NCT02870972
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01502046
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, One spray per day, up to a maximum of 12 sprays per day.
Study: NCT02500485
Drug: SHR3824, SP2086
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 100-mg tablet of SP2086 once daily on Day 1,2,3,4 followed by two 10-mg tablets of SHR3824 once daily on Day 11,12,13,14, followed by one 100-mg tablet of SP2086 and two 10-mg tablets of SHR3824 on Day 15,16,17,18.
Study: NCT01795599
Drug: Gymiso®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02667106
Drug: RX0041-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetic study
Study: NCT03792490
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to Fasudil hydrochloride hydrate, NaCl 0,9%
Study: NCT00867698
Drug: AST-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: AST-120
Study: NCT00203047
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for prednisone given daily
Study: NCT00662597
Drug: ASA404
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00662597
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01537692
Drug: BDP HFA Nasal Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP HFA Nasal 80mcg
Study: NCT01537692
Drug: BDP HFA Nasal Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP HFA Nasal 320mcg
Study: NCT03908892
Drug: zanthoxylum nitidum tincture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local application with zanthoxylum nitidum tincture soaked blocks for the sick nail(s) for 30 minutes, twice a day.
Study: NCT03908892
Drug: tetracycline ointment
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local use of 1% tetracycline ointment for the sick nail(s), 3 times a day
Study: NCT04435392
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01333085
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00025077
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01249846
Drug: PerioChip ®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02506751
Drug: liothyronine
Normalized name: Liothyronine
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All eligible subjects will be treated with the study drug as per the standardized dose-escalation protocol. Subjects will be required to report to the study site every six weeks for the duration of the study in order to receive their study drug and to monitor drug safety and tolerability.
Study: NCT04389034
Drug: Pollinex Quattro with tree- and grass pollen extracts and their mixtures
Normalized name: Brazilian pepper tree pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: retrospective analysis of patient records of allergen-specific immunotherapy
Study: NCT02205775
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 + 40 mg before PCI
Study: NCT02205775
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg twice before PCI (+ 10 mg ezetimibe)
Study: NCT02205775
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice before PCI
Study: NCT02029040
Drug: 0.9 % normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Within 5-15 minutes following the administration of the study drug, the Respiratory Distress Assessment Instrument (RDAI) score will be reassessed and study interventions are complete. The patient will be observed for one hour in the emergency department (ED). However, further treatments may be started immediately upon discretion of the treating physician. If the patient is discharged home study PI and/or research assistant will call the parents 7 days from the ED visit to check the number of visits to their primary doctor and/or EDs due to same illness.
Study: NCT01253122
Drug: TRx0037
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02947100
Drug: SCD-Omegatex™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive SCD-Omegatex™ (Enteric Fish Oil 250 DHA/27 EPA Soft Gelatin Capsule, 450 mg) at one of two daily doses, orally, once a day for 6 months. The trial will follow a 3+3 design using two dose levels. In the phase I portion, subjects will be treated with a dose of 25 mg/kg/day DHA and EPA. If this is tolerated without dose limiting toxicity (DLT), a subsequent cohort of patients will be treated at a dose of 37.5 mg/kg/day with a maximum total daily dose of 4 grams. Once a maximum tolerated dose (MTD) is determined, subjects on the phase II portion of the study will be treated at that dose.
Study: NCT01442272
Drug: Hidroferol®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hidroferol® drinkable ampoule in oral solution, 266 mcg (1 drinkable ampoule) each 15 days during 12 months
Study: NCT00573547
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine will be dosed at 90 mg once a week
Study: NCT00664703
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
Study: NCT01630590
Drug: Androgen Ablation Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen ablation therapy, either by means of luteinizing hormone-releasing hormone super-agonist (of any formulation), LHRH antagonist, or surgical castration given upon decision of study doctor.
Study: NCT03080493
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Packaged identical to gabapentin dosing
Study: NCT03080493
Drug: acetaminophen/codeine and ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Over the counter analgesic medications
Study: NCT02590068
Drug: Zoster vaccine live
Normalized name: zoster vaccine live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Zostavax vaccine, 0.65 ml dose, administered subcutaneously
Study: NCT00005871
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03450499
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: the analgesic requirement will be calculated in placebo group.
Study: NCT00940745
Drug: conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: dehydrating agent, haemostatic In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
Study: NCT01712061
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three or four tablets (50mg) daily for 12 weeks, depending on baseline renal function
Study: NCT02844777
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg applied once-daily for 28 days
Study: NCT02844777
Drug: 5% VDA-1102
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg applied once-daily for 28 days
Study: NCT02844777
Drug: 10% VDA-1102
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg applied once-daily for 28 days
Study: NCT00762476
Drug: 3804-250A
Approvals — FDA: no, EMA: no, PMDA: no
Description: * topical product~* apply 2 pumps~* apply at least every 4 hours or after hand washing
Study: NCT00762476
Drug: 3804-291
Normalized name: POUCH,OSTOMY H#3804
Approvals — FDA: no, EMA: no, PMDA: no
Description: * topical~* apply 2 pumps~* apply at least every 4 hours or after hand washing
Study: NCT01551368
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical inactive tablets.
Study: NCT01882764
Drug: HMPL-004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remitters and responders from HMPL-004 Induction study and patients complete the 8-week Open Label Induction Phase will be given HMPL-004 orally three times per day with total daily dose of 1800 mg for 52 weeks.
Study: NCT01882764
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remitters and responders from HMPL-004 Induction study and patients complete the 8-week Open Label Induction Phase will be given Placebo orally three times per day with total daily dose of 1800 mg for 52 weeks.
Study: NCT00303238
Drug: Rose hips extract + resveravine + Aframomum melegueta extract
Normalized name: Aframomum angustifolium seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02969980
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 50 mg/kg/day i.v. daily on days 3 and 4 of hematopoietic cell transplantation
Study: NCT01182727
Drug: salsalate
Normalized name: Salsalate
DrugBank: Salsalate (DB01399)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salsalate will be administered in 500 mg tablets. Salsalate will be administered in two divided doses of 2 grams in the morning and 2 grams in the evening. Salsalate will be administered for a total of 6 weeks. If a participant is not able to tolerate the target dose of 4 grams per day then 500 mg reductions will be made in a stepwise fashion until tolerated or a minimum dose of 2 grams per day is achieved.
Study: NCT01055704
Drug: Codeine only
Normalized name: Codeine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg taken orally four times daily for 5 days
Study: NCT01055704
Drug: Methylnaltrexone + codeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylnaltrexone 0.30 mg/kg by subcutaneous injection once daily and codeine 30 mg taken orally four times daily for 5 days
Study: NCT01055704
Drug: Placebo + placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneous injection once daily and placebo taken orally four times daily for 5 days
Study: NCT02223247
Drug: TVB-2640
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02351882
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to placebo arm, will undergo a one-week placebo washout, followed by 6 weeks of drug matched placebo (weeks 1-6). Participants will then receive a one-week placebo washout (week 7), before receiving 6 weeks of nabilone treatment (weeks 8-14).
Study: NCT03657264
Drug: P03277 0.1 mmol/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous bolus injection at 2 mL/sec
Study: NCT03657264
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous bolus injection at 2 mL/sec
Study: NCT03657264
Drug: P03277 0.3 mmol/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous bolus injection at 2 mL/sec
Study: NCT00880321
Drug: GSK2118436
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation with GSK2118436 may proceed until either a maximum tolerated dose is established, or the toxicokinetic safety limit is reached.
Study: NCT00636935
Drug: Antibiotics only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic only for treatment for mild (pO2 \> 70mmHg) PCP. Antibiotic Treatment with Bactrim, Pentamidine, Atovaquone, Primaquine/Clindamycin, or Trimethoprim/Dapsone.
Study: NCT00636935
Drug: Antibiotics + Corticosteroids
Normalized name: Antibiotics and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 40mg orally twice daily for 11 days, followed by 40mg once daily for 5 days, followed by 20mg once daily for 5 days and antibiotics (Bactrim, Pentamidine, Atovaquone, Primaquine/Clindamycin, or Trimethoprim/Dapsone).
Study: NCT00636935
Drug: Corticosteroids + antibiotics
Normalized name: Antibiotics and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs will be prescribed per standard of care for patients with PCP and pO2 \< 70mmHg.
Study: NCT05840068
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: The standard chemotherapy protocol developed by the South Egypt Cancer Institute (SECI).
Study: NCT00880321
Drug: GSK2118436
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 2 will use the recommended Part 2 dose of GSK2118436 identified during Part 1 of the study. Biologically active doses will be identified by measurement of pharmacodynamic markers in tumor tissue and blood across a range of doses and these doses may be explored in Part 2.
Study: NCT02424552
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filling material: lactose monohydrate, cellulose, magnesium stearate
Study: NCT03799913
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300mg/m2/d
Study: NCT00899977
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT03504735
Drug: Caduet Pill
Normalized name: Caduet Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take once daily.
Study: NCT03504735
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take once daily.
Study: NCT02848612
Drug: anticoagulation by unfractionated heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: anticoagulation by unfractionated heparin
Study: NCT00659659
Drug: MEDI-563
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg, 200 mg SC
Study: NCT01116921
Drug: Surfactants, Pulmonary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curosurf®, Chiesi USA, Inc., Cary, NC
Study: NCT03877705
Drug: Listerine ready tabs
Normalized name: Listerine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technically, it's a rectangular-shaped, bilayer-compressed tablet that once chewed, creates just enough liquid to swish around your mouth to get a whole-mouth clean feeling.As manufacture claimed the tablet is easy to use just in three simple steps: chew (to activate), swish (to clean), then swallow as unlike mouthwashes which may contain alcohol and other ingredients not intended for ingestion, Listerine Ready Tabs are alcohol-free and safe to swallow which is highly suitable for bedridden patients.
Study: NCT01544634
Drug: Qvar 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qvar 50, 1 puff bd for 6 weeks
Study: NCT01544634
Drug: Qvar 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qvar 100, 2 puffs bd for 6 weeks
Study: NCT00005964
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005964
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01898520
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oromucosal spray containing ethanol: propylene glycol(50:50) excipients, with peppermint oil (0.05%) flavouring and colourings FD\&C Yellow No.5 (E102 tartrazine) (0.0260%), FD\&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD\&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD\&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%). Each 100 μL spray administered to the sub-lingual or oral mucosa delivered the colourants plus excipients. The maximum daily dose was 12 sprays per day.
Study: NCT04041973
Drug: Artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet AL contains 20 mg artemether and 120 mg lumefantrine~The prophylaxis will start with a 3-day course of twice daily AL. This will be followed by 2 doses 8 hours apart on one day per week for up to 3 28-35 day consecutive follow-up periods and for 4 weeks after leaving the forest.
Study: NCT00902811
Drug: AM(FDC)
Normalized name: Encora AM Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate-mefloquine fixed dose combination (artesunate 25mg/mefloquine hydrochloride 55mg, or artesunate 100mg/mefloquine hydrochloride 220mg), according to age-group.
Study: NCT00902811
Drug: AM(LT)
Normalized name: Encora AM Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate (Arsumax®, Sanofi) 50 mg tabs given at 4 mg/Kg/day on day 0, day 1 and day 2 (total 12 mg/Kg) PLUS Mefloquine 250 mg base tabs given at 25 mg/Kg on day 0. Treatment is given in three equally divided daily doses to the nearest quarter tablet.
Study: NCT00902811
Drug: AA(FDC)
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate-amodiaquine fixed dose combination (FDC) (Artesunate Amodiaquine Winthrop® Sanofi Aventis); Artesunate 25mg/amodiaquine 67.5mg; Artesunate 50mg/amodiaquine 135mg ; Artesunate 100mg/amodiaquine 270mg